Stocktoria
Verrica Pharmaceuticals Inc. VRCA
Verrica Pharmaceuticals Inc. (VRCA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $35.6M at a -50.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.554 |
| Retained earnings / assets | -6.894 |
| EBIT / assets | -0.259 |
| Equity / liabilities | 1.105 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | 5/9 | -19.42 | — | — |
| ETST | Earth Science Tech, Inc. | 4/9 | — | 12.7 | +7.8% |
| SBFM | Sunshine Biopharma Inc. | 4/9 | -1.63 | — | +4.1% |
| BGM | BGM Group Ltd. | 5/9 | 7.99 | — | +51.1% |
| ZOMDF | Zomedica Corp. | 3/9 | 1.07 | — | +17.4% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
FAQ
Is VRCA financially healthy?
Verrica Pharmaceuticals Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VRCA pay a dividend?
No, Verrica Pharmaceuticals Inc. does not currently pay a dividend.
How profitable is VRCA?
In FY2025, Verrica Pharmaceuticals Inc. had a net margin of -50.3% and a return on equity of -72.3%.
What is the analyst price target for VRCA?
The average Wall-Street price target for Verrica Pharmaceuticals Inc. is $15.54, about 205.4% above the recent price, from 5 analysts (consensus: strong buy).
Is VRCA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Verrica Pharmaceuticals Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.